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lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study
Cesare Gridelli, Ciro Gallo, Anna Ceribelli, Vittorio Gebbia, Teresa Gamucci, Fortunato Ciardiello, Francesco Carozza, Adolfo Favaretto, 
Bruno Daniele, Domenico Galetta, Santi Barbera, Francesco Rosetti, Antonio Rossi, Paolo Maione, Francesco Cognetti, Antonio Testa, 
Massimo Di Maio, Alessandro Morabito, Francesco Perrone, on behalf of the GECO investigators.
Summary 
Background The addition of cyclo-oxygenase-2 (COX-2) inhibitors and prolonged constant infusion (PCI) of 
gemcitabine to treatment for advanced non-small-cell lung cancer (NSCLC) might improve treatment effi  cacy. We 
aimed to assess whether the addition of rofecoxib or PCI gemcitabine could improve overall survival compared with 
fi rst-line treatment with cisplatin plus gemcitabine given by standard infusion. 
Methods Patients with stage IV or IIIb (with supraclavicular nodes or pleural eff usion) NSCLC who were under 70 years 
of age and who had performance status 0 or 1 were eligible for this multicentre, prospective, open-label, randomised 
phase III trial with 2×2 factorial design. Patients were randomly assigned to one of four treatment groups: group A, 
gemcitabine 1200 mg/m2 in a 30-min intravenous infusion on days 1 and 8 and intravenous cisplatin 80 mg/m2 on day 1, 
every 21 days for six cycles; group B, the same treatments as group A plus oral rofecoxib 50 mg/day until disease 
progression; group C, intravenous PCI gemcitabine 1200 mg/m2 in a 120-min infusion on days 1 and 8 and intravenous 
cisplatin 80 mg/m2 on day 1, every 21 days for six cycles; group D, the same drugs as group C plus oral rofecoxib 
50 mg/day until disease progression. The primary endpoint was overall survival; secondary endpoints were progression-
free survival, response rate, quality of life, and toxicity. Analyses were intention-to-treat. This trial is registered on the 
clinical trials site of the US National Institutes of Health website http://clinicaltrials.gov/ct/show/NCT00385606.
Findings Between Jan 30, 2003, and May 3, 2005, 400 patients were enrolled. Median age was 60 years (range 29–71). 
PCI gemcitabine did not improve overall survival (median 47 weeks [95% CI 40–55] vs 44 [36–52], with standard 
gemcitabine infusion, hazard ratio (HR) of death 0·93 [0·74–1·17], p=0·41), progression-free survival, nor any other 
secondary endpoint. Vomiting and fatigue were signifi cantly worse with PCI gemcitabine. The two rofecoxib groups 
were closed early (on Oct 1, 2004) due to withdrawal of the drug because of safety issues. With intention-to-treat 
statistical analyses limited to 240 patients (ie, those randomised before July 1, 2004) who had at least 3 months of 
treatment, rofecoxib did not prolong overall survival (median 44 weeks [CI 36–55] vs 44 [40–54] without rofecoxib, and 
HR of death 1·00 [0·75–1·34], p=0·85), or progression-free survival, but did improve response rate (41% vs 26%, 
p=0·02), global quality of life, physical, emotional and role functioning, fatigue, and sleeping. Rofecoxib signifi cantly 
increased the incidence of diarrhoea and decreased constipation, fatigue, fever, weight loss, and pain, and analgesic 
consumption. Severe cardiac ischaemia was more frequent with rofecoxib than without; however, the diff erence was 
not statistically signifi cant in the primary analysis (p=0·06) and became signifi cant when patients who were 
randomised between July 1, 2004, and Sept 30, 2004, were included in the analysis (p=0·03).
Interpretation Neither PCI gemcitabine nor rofecoxib prolonged survival in the patients in this study. Rofecoxib 
improved response rate and several quality-of-life items, including pain-related items and global quality of life. Further 
studies with less cardiotoxic COX-2 inhibitors are needed in NSCLC. 
Introduction 
Prognosis of patients with advanced non-small-cell lung 
cancer (NSCLC) is poor. Platinum-based chemotherapy is 
the worldwide standard treatment, and on the basis of 
meta-analyses, is associated with a small, but signifi cant 
survival benefi t at 1 year in favour of cisplatin-containing 
regimens compared with best supportive care.1 However, 
the benefi t of chemotherapy is small and has to be weighed 
against substantial toxicity.2 Platinum-based treatment is 
associated with higher response rates compared with 
regimens that do not contain platinum, although, it does 
not prolong overall survival compared with regimens 
containing third-generation treatments (eg, taxanes, 
gemcitabine, and vinorelbine).3 Direct comparisons in 
phase III trials suggest that no major diff erences in effi  cacy 
exist between platinum-based treatments.4,5 
In Italy, the most commonly used treatment regimen is 
a combination of cisplatin and gemcitabine. Phos-
phorylation of gemcitabine to the monophosphate by 
deoxycytidine kinase is the rate-limiting step in the 
accumulation of the active diphosphate and triphos phate 
metabolites.6 Phase I studies have shown that the ability 
of mononuclear cells to accumulate gemcitabine 
triphosphate during treatment is saturable, and the 
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optimum plasma concentration of gemcitabine that 
maximised the rate of formation of gemcitabine 
triphosphate was about 20 µmol/L.7,8 By the use of dose 
rates of around 10 mg/m2/min, the target gemcitabine 
concentration in plasma was achieved, and the rate of 
gemcitabine triphos phate accumulation by mononuclear 
cells and leukaemia cells was optimised.9 In a phase II 
randomised trial in patients with pancreatic cancer, 
gemcitabine infused at the fi xed-dose rate infusion of 
10 mg/m2/min led to a median overall improvement in 
survival, with unusually high 1-year, 2-year, and 3-year 
survivorship compared with a dose-intense scheme of 
gemcitabine (2200 mg/m2) given in a standard 30-min 
infusion.10 In patients with NSCLC, the results of a 
randomised phase II study further showed the feasibility 
and activity of weekly gemcitabine at the fi xed-dose rate of 
10 mg/m2/min in combination with cis platin.11 In this 
particular study, median progression-free survival was a 
promising 8 months, although overall surv ival was similar 
to that in the standard group at 13 months. These data 
suggested that exposure to prolonged concentrations of 
gemcitabine might improve its effi  cacy.
Preclinical evidence lends support to the association 
between COX-2, prostaglandins, and cancer. COX is an 
important enzyme in the conversion of arachidonic acid to 
prostaglandins, which are involved in maintenance of the 
gastric mucosa, regulation of renal bloodfl ow, platelet 
aggregation, and immune response.12–14 Two isoforms of 
COX exist: COX-1 is constitutionally expressed, and COX-2 
is inducible by growth factors, oncogenes, carcinogens, 
and tumour-promoting phorbol esters.15 COX-2 is 
overexpressed in various human malignancies, and this 
overexpression represents an important early event in the 
development of some human tumours, including colon 
and lung cancer, and suggests that COX-2 is linked to the 
development of cancer.16,17 In patients with NSCLC, 
overexpression of COX-2 is associated with worse prognosis 
and with metastasis.18,19 Several preclinical studies have 
shown the in-vitro and in-vivo antitumoral activity of 
selective COX-2 inhibitors, which block tumour growth 
through many mechanisms, mainly by anti angiogenic and 
proapoptotic eff ects.20,21 Furthermore, syner gistic cyto-
toxicity has been reported in NSCLC cell lines with 
combinations of COX-2 inhibitors and several chemo-
therapeutic agents or radiotherapy.22–24 Based on these 
fi ndings, COX-2 inhibitors have been combined with 
chemotherapeutic agents in cancer treatment and early 
trials have documented the feasibility, good tolerability, 
and promising activity of such combinations in patients 
with advanced colorectal cancer and NSCLC.25,26 Rofecoxib 
is a selective COX-2 inhibitor that has ten-times greater 
biochemical selectivity for COX-2 than does celecoxib.27 
When the current study was planned, pub lished research 
suggested that a rofecoxib dose of 50 mg/day was feasible 
for prolonged treatment and was associated with a lower 
risk of gastrointestinal adverse events com pared with non-
steroidal anti-infl ammatory drugs.28–30 
The aim of this study was to assess whether the effi  cacy 
of cisplatin plus gemcitabine chemotherapy for NSCLC 
could be improved by the addition of rofecoxib or by a 
prolonged constant infusion (PCI) of gemcitabine. 
Methods
Patients and procedures
This was a multicentre, prospective, open-label, ran-
domised, factorial phase III trial. The study protocol was 
approved by the Ethics Committee of each participating 
institution and all patients provided written informed 
consent.
Patients with histologically or cytologically confi rmed 
NSCLC, stage IV or stage IIIB disease with malignant 
pleural eff usion or supraclavicular nodes, who were under 
70 years of age, had an Eastern Cooperative Oncology 
Group performance status of 0 or 1, and who had not 
received previous chemotherapy were recruited. Patients 
who had had previous radiotherapy that was completed at 
least 4 weeks before enrolment were allowed into the 
study. Patients with asymptomatic brain metas tases were 
eligible if radiotherapy was not needed concomitantly 
with chemotherapy. Patients were excluded if they had a 
history of previous invasive malignancy or inadequate 
bone marrow function (neutrophils <2×106 cell/L, platelets 
<100×109 cells/L, haemoglobin <100 g/L), inadequate 
hepatic function (alanine amino transferase, aspartate 
aminotransferase, or bilirubin >1·25×upper normal limit) 
in the absence of liver metastases, or alanine 
aminotransferase and aspartate aminotransferase over 
2·5×upper normal limit and bilirubin over 1·5×upper 
normal limit in the presence of liver metastases; or 
inadequate renal function (serum creatinine >1·25×upper 
normal limit). Previous  treatment with COX-2 inhibitors 
or systematic use of aspirin were not reasons for exclusion. 
Aspirin treatment could be continued during the study.
Patients were randomly assigned to one of four 
treatment groups: patients randomised to group A 
received gemcitabine 1200 mg/m2 in 30-min intravenous 
infusions on days 1 and 8, and intravenous cisplatin 
80 mg/m2 on day 1, every 21 days for six cycles; patients 
in group B received the same treatment as group A plus 
oral rofecoxib 50 mg per day until disease progression; 
patients in group C received PCI gemcitabine 1200 mg/m2 
over 120-minute infusions on days 1 and 8, and 
intravenous cisplatin 80 mg/m2 on day 1, every 21 days 
for six cycles; patients in group D received the same 
treatment as group C plus oral rofecoxib 50 mg per day 
until disease progression. The study protocol advised that 
a proton pump inhibitor at standard doses be prescribed 
for patients receiving rofecoxib to prevent gastrotoxicity. 
Use of a proton pump inhibitor in the control group was 
at the investigator’s discretion. The proton pump 
inhibitor could be any of the drugs registered in this class 
in Italy at standard dose (ie, omeprazole 20 mg/day, 
lansoprazole 30 mg/day, patoprazole 20–40 mg/day, or 
rabeprazole 20 mg/day).
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Dose reductions of chemotherapy were not planned, but 
treatment could be delayed for up to 2 weeks when toxicity 
caused by previous cycles had not resolved completely. 
The prophylactic use of granulocyte-colony-stimulating 
factors (G-CSF) and erythropoietin was not allowed. The 
use of G-CSF (the protocol did not specify which G-CSF 
was to be used; fi lgrastim and lenograstim were available 
in Italy during the study and 5μg/kg/day of either were 
planned) was recom mended for grade 4 neutropenia, even 
without fever. The use of epoetin alfa (10 000 IU/L three 
times a week) was allowed for anaemia according to its 
existing indica tion (haemoglobin ≤105 g/L). Second-line 
treatments were not prespecifi ed, but were decided on a 
case-by-case basis by the treating investigator.
All assessments were planned to be the same across all 
treatment groups. Patients were assessed at baseline with 
a complete history and physical examination, routine 
haematology and biochemistry, electrocardiogram (ECG), 
chest radiography, and CT scan of the head, chest, and 
abdomen. Routine haematology, biochemistry, and phys-
ical examination were done every 3 weeks, before the 
administration of successive cycles; haematology was also 
repeated before administration of chemotherapy on day 8 
of each cycle. Chest radiography, CT scans, and ECG were 
repeated after three and six cycles of chemotherapy. 
Clinical assessment and routine haematology and 
biochemistry were done every 2 months after the 
completion of chemotherapy. All examinations were done 
by investigators at each participating centre. 
Toxicities were assessed using the National Cancer 
Institute Common Toxicity Criteria version 2.0. Response 
was measured by the use of the Response Evaluation 
Criteria In Solid Tumors (RECIST). Complete response 
was defi ned as the disappearance of all target and non-
target tumours and no new tumours, as assessed by 
radiological tests; partial response was defi ned as a 
disappearance or a decrease of at least 30% in the sum of 
longest diameters of target tumours, combined with the 
disappearance or no change of non-target tumours; 
progression was defi ned as a 20% or greater increase in 
the sum of longest diameters of target tumours or as a 
clinically evident increase of non-target tumours or the 
appearance of a new tumour; all remaining cases were 
defi ned as stable disease. No central or independent 
verifi cation of response was used. No central review of 
histology was done; histology was assessed according to 
common practice at each participating centre. 
Quality of life was assessed using the European 
Organization for Research and Treatment (EORTC) 
QLQ-C30 questionnaire (version 3.0) and the lung 
cancer specifi c module (QLQ–LC13). Patients were 
asked to complete the questionnaires at baseline day 8 
cycle 1 and at the end of the fi rst three cycles. Additionally, 
pain was assessed by the use of a visual analogue scale 
at baseline and before each chemotherapy administration. 
Analgesic use was recorded for each patient from 
baseline through to the end of the fi rst three cycles of 
chemotherapy.  
Statistical analysis
Two comparisons were planned, combining the treatment 




cisplatin + standard gemcitabine
 60 from Jan 30, 2003 to June 30, 2004
  75 from Jan 30, 2003 to Sept 30, 2004*
125 from Jan 30, 2003 to May 3, 2005
99 Dead
26 Alive
     7 followed <6 months
     2 followed 6–12 months
   17 followed >12 months
125 for gemcitabine analysis
  60 for primary rofecoxib analysis
   75 for supplemental rofecoxib analysis*
  75 for gemcitabine analysis
  60 for primary rofecoxib analysis
   75 for supplemental rofecoxib analysis*
126 for gemcitabine analysis
  61 for primary rofecoxib analysis
   75 for supplemental rofecoxib analysis*
  74 for gemcitabine analysis
  59 for primary rofecoxib analysis
   74 for supplemental rofecoxib analysis*
57 Dead
18 Alive (1 refusal†)
     4 followed <6 months
     2 followed 6–12 months
   12 followed >12 months
58 Dead
16 Alive
     4 followed <6 months
     1 followed 6–12 months
   11 followed >12 months
93 Dead (1 refusal‡)
33 Alive 
     5 followed <6 months
     3 followed 6–12 months
   25 followed >12 months
Group B:
cisplatin + standard gemcitabine +
rofecoxib
 60 from Jan 30, 2003 to June 30, 2004
  75 from Jan 30, 2003 to Sept 30, 2004*
Group C:
cisplatin + PCI gemcitabine
  61 from Jan 30, 2003 to June 30, 2004
  75 from Jan 30, 2003 to Sept 30, 2004*
126 from Jan 30, 2003 to May 3, 2005
Group D:
cisplatin + PCI gemcitabine + rofecoxib
  59 from Jan 30, 2003 to June 30, 2004




Figure 1: Study fl ow according to Consort statement 
*Data reported in webappendix. †Patient was immediately lost to follow-up. ‡Patient received single-agent gemcitabine in standard 30-min infusion.
The three diff erent values reported in the allocation section derive from rofecoxib withdrawal and choice made for statistical analyses (see text for explanation). 
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gemcitabine, groups A and B (standard gemcitabine) were 
compared with groups C and D (PCI gemcitabine); second, 
when assessing the effi  cacy of rofecoxib, groups A and C 
(no rofecoxib) were compared with groups B and D (plus 
rofecoxib). Accordingly, except for baseline values, results 
have been reported separately for the two comparisons.
The primary endpoint was overall survival defi ned as the 
time from the date of randomisation to the date of death 
from any cause, or the date of last follow-up for living 
patients. 400 patients and about 200 deaths were required 
for each comparison to have 80% power of detecting a 0·67 
hazard ratio (HR) of death, with two-tailed signifi cance 
level of 0·05 (East software). This would represent an 
increase in median overall survival from 8 months in the 
control groups (similar to that reported in comparable 
Italian patients enrolled in a previous trial by the same 
researchers31) to 12 months in the experimental groups 
(supp orted by a randomised phase II trial of PCI 
gemcitabine in NSCLC11). Patients were randomised to the 
four treatment groups through an automated straight 
minimisation procedure that used centre, performance 
status (0,1), and disease stage (IIIB, IV) as strata; 
randomisation was done centrally by phone or fax at the 
coordinating centre (National Cancer Institute, Naples, 
Italy). Secondary end points were progression-free survival 
(defi ned as the time from the date of randomisation to the 
date of progression of disease, date of death from any cause 
for patients who died without progression, or date of last 
follow-up for patients without progression and alive at the 
end of the study), response, quality of life, and toxicity.
All effi  cacy analyses were done on an intention-to-treat 
basis. Overall survival and progression-free survival curves 
were estimated with the Kaplan-Meier method, and tested 
with a two-sided log-rank test. HR and 95% CI were estim-
ated by use of a Cox proportional hazards model that 
included treatment, gender, performance status (0, 1), dis-
ease stage (IIIb, IV), tumour histology (squamous, adeno-
carcinoma, other) and centre (three categories according to 
size: large, with more than 30 patients enrolled; medium, 
with 11–30 patients enrolled; small, with 1–10 patients 
enrolled) as covariates. 
All enrolled patients were included in the assessment 
of response, including those who had no measurable 
tumours at baseline. Contingency tables and the χ2 test 
without Yates’ correction were applied. The response rate 
was defi ned as the number of complete plus partial 
responses divided by the total number of patients enrolled 
in each comparison group. An additional descriptive 
analysis of response limited to target tumours was dec-
ided retrospectively for the rofecoxib comparison, driven 
by the result of the primary response rate analysis.
All patients who received treatment were included in the 
toxicity analysis. Statistical analysis of toxicity was done in 
two ways: fi rst, an exact linear permutation test was applied 
to acknowledge the ordinal nature of toxicity grades (Cytel 
7 software); second, an exact χ2 test was applied that 
compared severe (grades 3–5) versus not severe (grades 
0–2) toxicity. Cardiac and vascular toxic events are usually 
reported as summary outcomes; however, because of the 
known toxic eff ects of rofecoxib, we decided retrospectively 
Variable Group A: cisplatin + 
standard gemcitabine 
n=125
Group B: cisplatin + standard 
gemcitabine + rofecoxib 
n=75
Group C: cisplatin + PCI 
gemcitabine 
n=126
Group D: cisplatin + PCI 
gemcitabine + rofecoxib 
n=74
Median age, years (range) 59 (37–70) 61 (29–71) 59 (38 –69) 62 (38–70)
Performance status, n (%)
0 63 (50) 38 (51) 65 (52) 36 (49)
1 62 (50) 37 (49) 61 (48) 38 (51)
Stage of disease, n (%)
IIIb 13 (10) 10 (13) 15 (12) 11 (15)
IV 112 (90) 65 (87) 111 (88) 63 (85)
Sex, n (%)
Men 98 (78) 63 (84) 104 (83) 57 (77)
Women 27 (22) 12 (16) 22 (17) 17 (23)
Histology, n (%)
Squamous-cell carcinoma 28 (22) 25 (33) 25 (20) 22 (30)
Adenocarcinoma 64 (51) 33 (44) 70 (56) 35 (47)
Large-cell carcinoma 6 (5) 4 (5) 5 (4) 1 (1)
Mixed 2 (2) 4 (5) 3 (2) 2 (3)
Undefi ned 25 (20) 9 (12) 23 (18) 14 (19)
Size of centre, n (%)
Large (>30 patients) 50 (40) 26 (35) 32 (25) 18 (24)
Medium (11–30 patients) 37 (30) 23 (31) 45 (36) 28 (38)
Small (1–10 patients) 38 (30) 26 (35) 49 (39) 28 (38)
Table 1: Baseline characteristics of enrolled patients
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to describe and analyse them both as summary outcomes 
and as specifi c items to give maximum information. 
Quality-of-life data were analysed according to the 
recommendations of the EORTC QLQ-C30 Scoring 
Manual. Diff erences from baseline were calculated for all 
single items of the questionnaires, global quality-of-life 
scores, and pain visual analogue scales. Diff erences in 
quality-of-life between the treatment groups were compared 
by the use of the Wilcoxon rank sum test. No previous data 
on safety of the three innovative treatment combinations 
were available; therefore, an early analysis of safety, nested 
within the phase III trial, was planned for the three 
experimental groups (B, C, and D). The same Simon’s 
optimum two-stage design was applied to each group with 
unacceptable toxicity as the endpoint: by setting the 
minimum acceptable proportion of patients with no 
unacceptable toxicity (p0) equal to 0·55, the desirable 
proportion of patients with no unacceptable toxicity (p0) 
equal to 0·75, and the error probabilities α and β both 
equal to 0·10, eight or more cases of unacceptable toxicity 
in the fi rst 18 patients would have led to halting that 
treatment group. At the second stage, 41 patients per group 
were needed, and enrolment would have been stopped for 
any group with 15 or more cases of unacceptable toxicity. If 
the second stage was passed, enrolment would continue as 
planned for the phase III study. Unacceptable toxicity was 
defi ned as the occurrence within the fi rst three cycles of 
any of the following: febrile neutropenia, grade 3–4 
neutropenia with infection, any grade 4 anaemia, 
thrombocytopenia, vomiting, mucositis, diarrhoea, constip-
ation, fatigue, or fever, any other grade 3–4 toxicity, any 
toxicity inducing a severe worsening of general condition 
that prevented restaging, or any toxicity that in the 
judgment of physicians induced early suspension of 
treatment for reasons other than progression. 
Rofecoxib withdrawal
Enrolment into the study began on Jan 30, 2003. On Oct 1, 
2004, rofecoxib was withdrawn by the US Food and Drug 
Administration, European Medicines Agency, and Italian 
Drug Agency. 299 patients had been randomised up to the 
date of rofecoxib withdrawal. The two groups that included 
rofecoxib were closed to further enrolment and the ongoing 
treatments with rofecoxib were stopped, although 
chemotherapy plans did not change for these patients. The 
study continued as planned for the two gemcitabine groups 
and the last patient was enrolled on May 3, 2005. Due to 
these changes in enrolment and ongoing treatment, we 
decided to include only the 240 patients who were enrolled 
up to June 30, 2004, in the statistical analyses of the 
rofecoxib groups to allow for data on at least 3 months of 
treatment with rofecoxib. This choice diminishes the power 
of the analyses, but decreases the risk of underestimating 
toxicity and the risk of diluting the possible therapeutic 
eff ect of rofecoxib. For the gemcitabine analyses, all 
randomised patients were considered, without any cut-off  
date. Patients recruited between Sept 30, 2004, and May 3, 
2005, were included in the gemcitabine analyses only. 
Endpoint Gemcitabine infusion rate Rofecoxib
Standard (n=200) PCI (n=200) HR* (95% CI) p Without (n=121) With (n=119) HR* (95% CI) p
Overall survival
Events, n (%) 155 (78) 150 (75) .. .. 94 (78) 94 (79) .. ..
Median, weeks (95% CI) 44 (36–52) 47 (40–55) 0·93 (0·74–1·17) 0·41†; 0·52‡ 44 (40–54) 44 (36–55) 1·00 (0·75–1·34) 0·85†; 1·00‡
6-month probability 0·69 0·76 .. .. 0·70 0·73 .. ..
1-year probability 0·41 0·45 .. .. 0·40 0·42 .. ..
Time-to-progression
Events, n (%) 186 (93) 182 (91) .. .. 108 (89) 111 (93) .. ..
Median, weeks (95% CI) 22 (20–26) 23 (21–26) 0·97 (0·79–1·20) 0·65† 0·80‡ 23 (20–30) 25 (22–29) 1·00 (0·76–1·31) 0·98† 1·00‡
6-month probability 0·43 0·42 .. .. 0·43 0·47 .. ..
1-year probability 0·15 0·12 .. .. 0·15 0·14 .. ..
Overall objective tumour response 
Responses , n (%) 67 (34) 57 (29) .. 0·28§ 32 (26) 49 (41) .. 0·02§
95% CI 27–40 23–35 .. .. 19–35 33–50 .. ..
Description of tumour response, n (%)
Complete response 3 (2) 2 (1) .. .. 0 2 (2) .. ..
Partial response 64 (32) 55 (28) .. .. 32 (26) 47 (39) .. ..
Stable disease 51 (26) 62 (31) .. .. 43 (36) 24 (20) .. ..
Progression 59 (30) 47 (24) .. .. 27 (22) 24 (20) .. ..
Not assessed 23 (12) 34 (17) .. .. 19 (16) 22 (18) .. ..
*HR of events for patients in the experimental groups, after adjustment by size of centre, sex, performance status, stage, histological type of tumour, and other treatment factors. †From unadjusted log-rank test. 
‡From Cox model including size of centre, gender, performance status , stage, histological type of tumour, and other treatment factors as covariates. §From χ2 test.
Table 2: Effi  cacy outcomes
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A complete set of tables and fi gures reporting results of 
analyses done on data of all of the 299 patients enrolled up 
to Sept 30, 2004 is reported in the webappendix. 
Role of the funding source
The funding sources and the supplier of rofecoxib had no 
role in the study design, data collection, data analysis, 
data interpretation, or in the writing of this report. CGr, 
CGa, MDM, AM, and FP had full access to all the raw data. 
The corresponding author had full access to all the data 
and had fi nal responsibility for the decision to submit for 
publication. 
Results
Early safety analysis 
The early phase II safety assessment was done according 
to the protocol plan, and passed the threshold for both 
stages. The total number of patients with unacceptable 
toxicity was under the threshold of 15 for all experimental 
groups. In group B, six patients had unacceptable toxicity 
consisting of febrile neutropenia (grade 3, one patient), 
dyspnoea (grade 4, one patient), non-neutropenic infection 
(grade 3, one patient), epigastralgia (grade 3, one patient), 
and neurological (grade 3, one patient) and renal (grade 3, 
one patient) toxic events. In group C, eight patients had 
unacceptable toxicity consisting of sudden death (grade 5, 
one patient), ototoxicity (grade 3, two patients), peripheral 
artherial ischaemia (grade 3, one patient), dyspnoea plus 
anorexia (both grade 3, one patient), renal (grade 1) and 
hepatic (grade 3, one patient) toxic eff ects, physician’s 
decision to stop cisplatin (one patient), and worsening of 
general condition (one patient). In group D, fi ve patients 
had unacceptable toxicity consisting of deep venous 
thrombosis with pulmonary embolism (grade 4, one 
patient), anaemia (grade 4, one patient), bleeding (grade 4) 
with consequent anaemia (grade 4) and ischaemic heart 
attack (grade 4, one patient), thrombocytopenia (grade 3 
with mild bleeding, one patient), renal toxic eff ects 
(grade 2) with concomitant fatigue (grade 3, one patient).
Overall, 400 patients were randomised into the four 
groups (fi gure 1): 125 to group A (standard gemcitabine, 
cisplatin), 75 to group B (standard gemcitabine, cisplatin, 
rofecoxib), 126 to group C (PCI gemcitabine, cisplatin), 
and 74 to group D (PCI gemcitabine, cisplatin, rofecoxib). 
Two patients refused the assigned treatment after 
randomisation: one of these patients was assigned to 
group B and was lost to follow-up; the other was assigned 
to group C and received single-agent gemcitabine with 
standard 30-min infusion. Both these patients were 
removed from compliance and toxicity analyses, but were 
included in the analyses for the other outcomes according 
to the intention-to-treat strategy. 
Baseline characteristics of all randomised patients were 
balanced across the four treatment groups (table 1). Median 
age of patients was 60 years (range 29–71). Performance 
status was evenly divided between 0 and 1. 351 of 400 (88%) 
patients had stage IV disease. The study included more 
than four times as many male patients as female patients. 
Adenocarcinoma was the most frequent histological cancer 
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Figure 2: Overall survival (left panels) and progression-free survival (PFS; right panels) for PCI gemcitabine versus standard gemcitabine (upper panels) and 
for rofecoxib versus non-rofecoxib (lower panels) 
See Online for webappendix
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301 (52%) patients for whom we have data received second-
line chemotherapy, with large variation in the agent given 
(docetaxel, paclitaxel, vinorelbine, ifosfamide, carboplatin). 
In all com par isons, we did not note any statistically 
signifi cant diff erence in the numbers of patients receiving 
second-line treatment. 
Evaluation of PCI gemcitabine versus standard 
gemcitabine  
Three patients assigned to PCI gemcitabine crossed to the 
standard-rate infusion because of toxicity, after one cycle 
(two patients) and two cycles (one patient). Overall, 831 cycles 
were initiated with standard and 823 cycles with PCI 
gemcitabine; gemcitabine treatment on day 8 was omitted 
in 108 (13%) standard cycles and 139 (17%) cycles with PCI 
gemcitabine. The median number of cycles administered 
was fi ve (range 1–6) in both groups. 88 (44%) patients in the 
standard and 80 (40%) patients in the PCI gemcitabine 
groups completed six cycles. Treatment with cisplatin and 
gemcitabine was stopped for disease progression in 62 and 
59 patients, for toxicity in 37 and 37 patients, for refusal in 
six and 12 patients, for death in fi ve and eight patients, and 
Standard gemcitabine (n=199), n (%) PCI gemcitabine (n=199), n (%) p
0 1 2 3 4 5 0 1 2 3 4 5 WMW Fisher
Allergy 195 (98) 1 (<1) 3 (2) 0 0 0 196 (98) 2 (1) 1 (<1) 0 0 0 0·65 ..
Anaemia 89 (45) 56 (28) 38 (19) 14 (7) 2 (1) 0 91 (46) 35 (18) 48 (24) 21 (11) 4 (2) 0 0·36 0·19
Leucopenia 124 (62) 25 (13) 30 (15) 16 (8) 4 (2) 0 122 (61) 23 (12) 25 (13) 26 (13) 3 (2) 0 0·65 0·22
Neutropenia 106 (53) 17 (9) 29 (15) 35 (18) 12 (6) 0 96 (48) 17 (9) 24 (12) 40 (20) 22 (11) 0 0·14 0·12
Febrile neutropenia 195 (98) .. .. 3 (2) 0 1 (<1) 192 (96) .. .. 5 (3) 1 (<1) 1 (<1) 0·45 0·54
Neutropenic infection 197 (99) 0 1 (<1) 1 (<1) 0 0 194 (97) 0 2 (1) 3 (2) 0 0 0·36 0·62
Non-neutropenic infection 196 (98) 0 1 (<1) 2 (1) 0 0 194 (97) 1 (<1) 0 3 (2) 1 (<1) 0 0·49 0·69
Platelets 131 (66) 14 (7) 17 (9) 33 (17) 4 (2) 0 139 (70) 9 (5) 20 (10) 25 (13) 6 (3) 0 0·44 0·51
Haemorrhage 193 (97) 2 (1) 0 4 (2) 0 0 186 (93) 6 (3) 2 (1) 3 (2) 1 (<1) 1 (<1) 0·13 1·00
Heart rhythm 196 (98) 1 (<1) 2 (1) 0 0 0 198 (99) 1 (<1)  0 0 0 0 0·37 ..
Supraventricular arrhythmia 197 (99) 0 2 (1) 0 0 0 199 (100) 0 0 0 0 0 0·50 ..
Sinus tachycardia 198 (99) 1 (<1) 0 0 .. .. 198 (99) 1 (<1) 0 0 .. .. 1·00 ..
Heart general 186 (93) 0 2 (1) 2 (1) 6 (3) 3 (2) 184 (92) 0 1 (<1) 3 (2) 5 (3) 6 (3) 0·62 0·68
Cardiac ischaemia 196 (98) 0 1 (<1) 1 (<1) 1 (<1) 0 195 (98) 0 1 (<1) 1 (<1) 2 (1) 0 0·75 1·00
CNS ischaemia 195 (98) .. .. 1 (<1) 2 (1) 1 (<1) 197 (99) .. .. 0 1 (<1) 1 (<1) 0·65 0·69
Left ventricular function 199 (100) ..* ..* 0 0 0 198 (99) ..* ..* 1 (<1) 0 0 1·00 1·00
Peripheral arterial ischaemia 199 (100) .. 0 0 0 0 198 (99) .. 0 1 (<1) 0 0 1·00 1·00
Phlebitis (superfi cial) 198 (99) .. 1 (<1) .. .. .. 199 (100) .. 0 .. .. .. 1·00 ..
Thrombosis or embolism 195 (98) .. 0 1 (<1) 3 (2) 0 195 (98) .. 0 0 2 (1) 2 (1) 0·80 1·00
Sudden death 197 (99) .. .. .. .. 2 (1) 196 (98) .. .. .. .. 3 (2) .. 1·00
Kidney 184 (92) 7 (4) 7 (4) 1 (<1) 0 0 190 (95) 5 (3) 2 (1) 1 (<1) 1 (<1) 0 0·22 1·00
Pulmonary 188 (94) 3 (2) 5 (3) 0 2 (1) 1 (<1) 190 (95) 4 (2) 2 (1) 2 (1) 0 1 (<1) 0·60 1·00
Fatigue 108 (54) 36 (18) 50 (25) 5 (3) 0 0 113 (57) 27 (14) 45 (23) 13 (7) 1 (<1) 0 0·95 0·06
Fever 187 (94) 8 (4) 3 (2) 1 (<1) 0 0 182 (91) 12 (6) 5 (3) 0 0 0 0·39 1·00
Weight loss 189 (95) 6 (3) 3 (2) 1 (<1) 0 0 187 (94) 11 (6) 1 (<1) 0 0 0 0·82 1·00
Hair loss 168 (84) 15 (8) 16 (8) .. .. .. 161 (81) 14 (7) 24 (12) .. .. .. 0·32 ..
Skin 194 (97) 2 (1) 3 (2) 0 0 0 195 (98) 2 (1) 2 (1) 0 0 0 0·82 ..
Anorexia 177 (89) 11 (6) 9 (5) 2 (1) 0 0 167 (84) 13 (7) 16 (8) 2 (1) 1 (<1) 0 0·13 1·00
Constipation 165 (83) 19 (10) 13 (7) 2 (1) 0 0 173 (87) 17 (9) 9 (5) 0 0 0 0·23 0·50
Diarrhoea 186 (93) 7 (4) 6 (3) 0 0 0 177 (89) 10 (5) 8 (4) 4 (2) 0 0 0·09 0·12
Nausea 109 (55) 36 (18) 51 (26) 3 (2) 0 0 90 (45) 53 (27) 47 (24) 7 (4) 2 (1) 0 0·12 0·14
Stomatitis 184 (92) 6 (3) 6 (3) 3 (2) 0 0 182 (91) 10 (5) 5 (3) 2 (1) 0 0 0·82 1·00
Vomiting 142 (71) 24 (12) 27 (14) 5 (3) 1 (<1) 0 123 (62) 22 (11) 45 (23) 8 (4) 1 (<1) 0 0·02 0·60
Liver 185 (93) 11 (6) 2 (1) 1 (<1) 0 0 181 (91) 11 (6) 5 (3) 2 (1) 0 0 0·41 1·00
Auditory 185 (93) 4 (2) 10 (5) 0 0 .. 190 (95) 1 (<1) 6 (3) 2 (1) 0 .. 0·38 0·50
Neurological 182 (91) 4 (2) 10 (5) 3 (2) 0 0 178 (89) 17 (9) 4 (2) 0 0 0 0·61 0·25
Other 179 (90) 7 (4) 10 (5) 3 (2) 0 0 183 (92) 9 (5) 6 (3) 1 (<1) 0 0 0·41 0·62
Toxic deaths 194 (97) .. .. .. .. 5 (3) 190 (95) .. .. .. .. 9 (5) .. 0·42
 WMW=Wilcoxon Mann Witney exact test. Fisher=Fisher’s exact test comparing grade 0–1–2 versus 3–4–5. LVEF=Left ventricular ejection fraction. *LVEF measurement was not planned in asymptomatic patients. 
Table 3: Worst degree of toxic events as defi ned by NCI-CTC according to gemcitabine groups 
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for protocol violation in one and three patients, in the 
standard and PCI gemcitabine groups, respectively.
All patients were included in effi  cacy analyses (table 2). 
At the time of analysis, with 22 months of median follow-
up of alive patients (range 0–40), 305 (76%) patients had 
died and 368 patients (92%) had disease progression. 
Overall survival was not signifi cantly diff erent between 
treatment the groups (p=0·41, fi gure 2); median overall 
survival was 44 weeks (95% CI 36–52) with standard 
gemcitabine and 47 weeks (40–55) with PCI gemcitabine. 
At multivariate analysis, adjusted for gender, performance 
status, stage of disease, histotype, size of institution, and 
addition or not of rofecoxib, the HR of death for patients 
treated with PCI gemcitabine was 0·93 (0·74–1·17).  
The median progression-free survival was 22 weeks 
(20–26) in the standard groups and 23 weeks (21–26) in 
the PCI gemcitabine groups (HR 0·97 [0·79–1·20], 
p=0·65; fi gure 2). The overall response rate, including 
complete and partial responders, was 34% (27–40) for the 
standard groups and 29% (23–35) for the PCI gemcitabine 
groups (p=0·28). There was no prognostic value of 
histology in any of the multivariate models applied. 
Toxic eff ects are reported in table 3. Overall, there were 
14 toxic deaths that were possibly treatment-related, fi ve 
in the standard groups (one febrile neutropenia with 
septic shock, one stroke, one bronchial rupture, and two 
sudden deaths), and nine in the PCI gemcitabine groups 
(one febrile neutropenia with septic shock, one massive 
haem optysis, one stroke, two pulmonary embolisms, one 
acute dyspnoea, and three sudden deaths; exact p=0·42).
No signifi cant diff erence was noted in the occurrence 
and severity of all considered toxicities, with the exception 
of vomiting, which was more frequent and severe in the 
PCI gemcitabine groups; more severe fatigue (not stat ist-
ically signifi cant) was also found in the PCI gemcitabine 
groups. 
371 (93%) patients completed the baseline quality-of-
life assessments; compliance was similar in the two 
groups at baseline and at subsequent assessments during 
the treatment, and no statistical signifi cant diff erence 
was recorded for compliance in these assessments (data 
not shown). Baseline mean scores were comparable bet-
ween the two groups for all the items. Hair loss was the 
only item for which mean diff erences from baseline were 
signifi cantly worse for patients assigned PCI gemcitabine 
(17, 27, and 27 points after one, two, and three cycles) 
than for those receiving standard gemcitabine (8, 19, 18 at 
the same timepoints), with p values of 0·002, 0·02, and 
0·03 after one, two and three cycles, respectively.
Evaluation of the addition of refocoxib versus no 
rofecoxib
As reported above, analyses on rofecoxib are limited 
to patients enrolled up to June 30, 2004, (240 patients, 
119 with and 121 without rofecoxib) to allow for at least 
3 months of treatment with rofecoxib. However, a 
complete set of tables and fi gures reporting results of 
analyses done on data of all patients enrolled up to Sept 30, 
2004, (299 patients) is reported in the webappendix. No 
remarkable diff erences are apparent between the two 
sets of analyses. Baseline characteristics of patients are 
balanced between the two groups of the comparison.
One patient (in group B) refused the assigned treatment 
after randomisation and was immediately lost to follow-
up. Rofecoxib was administered to 118 patients (59 com-
bined with standard chemotherapy and 59 combined 
with cisplatin plus PCI gemcitabine; fi gure 1) for a median 
time of 14 weeks (range 0–64 [95% CI 10–18]). 33 patients 
received more than 6 months of treatment and one patient 
received rofecoxib for more than 1 year (64 weeks). 
Overall, 497 cycles of chemotherapy were initiated 
without rofecoxib and 494 cycles were started with 
rofecoxib; treatment with gemcitabine on day 8 was 
omitted in 80 (16%) and 67 (14%) cycles in the two groups, 
respectively. The median number of cycles administered 
was fi ve (range 1–6) in both groups. 
47 (39%) patients completed six cycles of chemotherapy in 
the groups without rofecoxib and 55 (46%) patients 
completed six cycles of chemotherapy in the groups with 
rofecoxib. Chemotherapy was stopped for disease progres s-
ion in 37 and 27 patients, for toxicity in 25 and 27 patients, 
for refusal in fi ve and eight patients, for death in six and one 
patients, and for protocol violation in one and one patient, 
in the groups without and with rofecoxib, respectively.
240 patients were included in the effi  cacy analyses 
(table 2). At the time of analysis, with 23 months median 
follow-up of alive patients (range 0–40), 188 (78%) had 
died and 219 patients (91%) had disease progression. 
Overall survival between treatment groups was not 
signifi cantly diff erent (p=0·85, fi gure 2), with median 
overall survival of 44 weeks in both groups (95% CI 40–54 
for the control groups and 36–55 for the rofecoxib 
groups); in multivariate analysis, adjusted for gender, 
–100 –30 20 100
Percent change in the size of measurable tumours (best response vs baseline value)
–100 –30 20 100
Figure 3: Description of target tumour best response for rofecoxib (right) and non-rofecoxib (left) groups
100% change represent a complete response. Green bars indicate objective responses (complete or partial); red 
bars indicate stable disease; blue bars indicate progressive disease. Plotted data refer to the best response ever 
recorded in each individual patient who had measurable tumours. 
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performance status, stage of disease, histotype, size of 
institution, and schedule of gemcitabine, the HR of death 
for patients assigned rofecoxib was 1·00 (0·75–1·34).  
Median progression-free survival was 23 weeks (20–30) 
in the groups not asigned rofecoxib and 25 weeks (22–29) 
in the groups assigned rofecoxib (p=0·98, HR 1·00 
[0·76–1·31]; fi gure 2). The overall response rate, including 
complete and partial responders, was 26% (19–35) for the 
groups not assigned rofecoxib and 41% (33–50) for the 
groups assigned rofecoxib; this diff erence was statistically 
signifi cant using χ2 test, with p=0·02. In fi gure 3, the 
percent change of the size of measurable tumours at the 
time of best response is reported in the two compared 
groups, without (left) and with rofecoxib (right). This 
graphical representation suggests that the positive eff ect 
of rofecoxib on response is not limited to a subgroup of 
patients. There was no prognostic value of histology in 
any of the multivariate models applied. 
Table 4 shows toxic events. We noted seven toxic deaths 
that were possibly treatment-related, six in the standard 
Without rofecoxib (n=120), n (%) With rofecoxib (n=118), n (%) P
0 1 2 3 4 5 0 1 2 3 4 5 WMW Fisher
Allergy 117 (98) 2 (2) 1 (<1) 0 0 0 114 (97) 1 (<1) 3 (3) 0 0 0 0·55 ..
Anaemia 51 (43) 29 (24) 26 (22) 12 (10) 2 (2) 0 54 (46) 27 (23) 26 (22) 9 (8) 2 (2) 0 0·59 0·67
Leucopenia 72 (60) 14 (12) 15 (13) 17 (14) 2 (2) 0 70 (59) 13 (11) 20 (17) 13 (11) 2 (2) 0 1·00 0·58
Neutropenia 62 (52) 10 (8) 15 (13) 18 (15) 15 (13) 0 55 (47) 7 (6) 20 (17) 25 (21) 11 (9) 0 0·52 0·67
Febrile nutropenia 117 (98) .. .. 2 (2) 0 1 (<1) 114 (97) .. .. 3 (3) 1 (<1) 0 0·68 0·72
Neutropenic infection 119 (99) 0 0 1 (<1) 0 0 115 (97) 0 1 (<1) 2 (2) 0 0 0·37 0·62
Non-neutropenic infection 118 (98) 0 0 2 (2) 0 0 117 (99) 0 0 1 (<1) 0 0 1·00 1·00
Platelets 82 (68) 6 (5) 11 (9) 17 (14) 4 (3) 0 80 (68) 8 (7) 9 (8) 19 (16) 2 (2) 0 1·00 1·00
Haemorrhage 115 (96) 2 (2) 0 3 (3) 0 0 110 (93) 3 (3) 0 4 (3) 1 (<1) 0 0·33 0·50
Heart rhythm 120 (100) 0 0 0 0 0 116 (98) 1 (<1) 1 (<1) 0 0 0 0·24 ..
Supraventricular arrhythmia 120 (100) 0 0 0 0 0 117 (99) 0 1 (<1) 0 0 0 0·50 ..
Sinus tachycardia 120 (100) 0 0 0 .. .. 117 (99) 1 (<1) 0 0 .. .. 0·50 ..
Heart general 113 (94) 0 1 (<1) 1 (<1) 1 (<1) 4 (3) 108 (92) 0 0 2 (2) 7 (6) 1 (<1) 0·48 0·31
Cardiac ischaemia 120 (100) 0 0 0 0 0 114 (97) 0 0 1 (<1) 3 (3) 0 0·06 0·06
CNS ischaemia 120 (100) .. .. 0 0 0 117 (99) .. .. 0 1 (<1) 0 0·50 0·50
Left ventricular function 120 (100) ..* ..* 0 0 0 117 (99) ..* ..* 1 (<1) 0 0 0·50 0·50
Peripheral arterial ischaemia 119 (99) .. 0 1 (<1) 0 0 118 (100) .. 0 0 0 0 1·00 1·00
Phlebitis (superfi cial) 119 (99) .. 1 (<1) .. .. .. 118 (100) .. 0 .. .. .. 1·00 ..
Thrombosis or embolism 117 (98) .. 0 0 1 (<1) 2 (2) 115 (97) .. 0 0 3 (3) 0 1·00 1·00
Sudden death 118 (98) .. .. .. .. 2 (2) 117 (99) .. .. .. .. 1 (<1) .. 1·00
Kidney 110 (92) 5 (4) 3 (3) 1 (<1) 1 (<1) 0 105 (89) 7 (6) 5 (4) 1 (<1) 0 0 0·50 1·00
Pulmonary 116 (97) 0 2 (2) 1 (<1) 0 1 (<1) 108 (92) 4 (3) 4 (3) 0 2 (2) 0 0·12 1·00
Fatigue 58 (48) 22 (18) 32 (27) 7 (6) 1 (<1) 0 78 (66) 13 (11) 23 (19) 4 (3) 0 0 0·008 0·38
Fever 110 (92) 9 (8) 1 (<1) 0 0 0 116 (98) 2 (2) 0 0 0 0 0·03 ..
Weight loss 109 (91) 9 (8) 1 (<1) 1 (<1) 0 0 116 (98) 2 (2) 0 0 0 0 0·02 1·00
Hair loss 102 (85) 8 (7) 10 (8) .. .. .. 99 (84) 5 (4) 14 (12) .. .. .. 0·75 ..
Skin 117 (98) 0 3 (3) 0 0 0 115 (97) 1 (<1) 2 (2) 0 0 0 1·00 ..
Anorexia 101 (84) 9 (8) 6 (5) 4 (3) 0 0 106 (90) 8 (7) 4 (3) 0 0 0 0·16 0·12
Constipation 93 (78) 13 (11) 12 (10) 2 (2) 0 0 105 (89) 12 (10) 1 (<1) 0 0 0 0·009 0·50
Diarrhoea 112 (93) 1 (<1) 7 (6) 0 0 0 100 (85) 11 (9) 6 (5) 1 (<1) 0 0 0·05 0·50
Nausea 62 (52) 23 (19) 31 (26) 4 (3) 0 0 60 (51) 28 (24) 28 (24) 1 (<1) 1 (<1) 0 0·82 0·68
Stomatitis 111 (93) 5 (4) 2 (2) 2 (2) 0 0 111 (94) 5 (4) 2 (2) 0 0 0 0·63 0·50
Vomiting 78 (65) 14 (12) 24 (20) 3 (3) 1 (<1) 0 78 (66) 15 (13) 21 (18) 4 (3) 0 0 0·81 1·00
Liver 109 (91) 7 (6) 3 (3) 1 (<1) 0 0 108 (92) 6 (5) 3 (3) 1 (<1) 0 0 0·93 1·00
Auditory 111 (93) 1 (<1) 6 (5) 2 (2) 0 .. 112 (95) 3 (3) 3 (3) 0 0 .. 0·39 0·50
Neurological 110 (92) 5 (4) 4 (3) 1 (<1) 0 0 107 (91) 7 (6) 3 (3) 1 (<1) 0 0 0·81 1·00
Other 109 (91) 3 (3) 7 (6) 1 (<1) 0 0 106 (90) 3 (3) 7 (6) 2 (2) 0 0 0·74 0·62
Toxic deaths 114 (95) .. .. .. .. 6 (5) 117 (99) .. .. .. .. 1 (<1) .. 0·12
WMW=Wilcoxon Mann Witney exact test. Fisher=Fisher’s exact test comparing grade 0–1–2 versus 3–4–5. LVEF=left ventricular ejection fraction.*LVEF measurement was not planned in asymptomatic patients. 
Table  4: Worst degree of toxic events according to rofecoxib groups
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groups and one in the rofecoxib groups (exact p=0·12). 
Patients given rofecoxib had a signifi cantly higher incid-
ence of diarrhoea, which was severe in one patient only, 
and had a much lower incidence of constipation than 
those not given rofecoxib. Additionally, patients given 
rofecoxib had signifi cantly less fatigue, fever, and weight 
loss. For heart toxicity, summary measures (heart rhythm 
and heart general) did not show statistically signifi cant 
diff erences. However, data scattered by subheadings of 
Common Toxicity Criteria showed a higher incidence of 
severe heart ischaemia (exact p=0·06). This comparison 
was statistically signifi cant (p=0·03 at exact Wilcoxon-
Mann-Whitney test and p=0·06 at exact Fisher test) in 
the analysis done on the dataset including patients 
randomised up to Sept 30, 2004, in which an additional 
patient developed ischaemia in the rofecoxib groups 
(webappendix tables).
221 patients (92%) completed the baseline quality-of-
life assessments with no statistical diff erence in 
compliance between the two groups at baseline and at 
subsequent assessments during the treatment (data not 
shown). Baseline mean scores were not statistically diff -
erent between the two groups for all the items, except for 
haemoptysis (p=0·03; data not shown). The most striking 
diff erences between groups in changes from baseline 
were reported in items that studied pain and use of 
analgesics, which all favoured the rofecoxib group. Less 
evident, but frequently signifi cant diff erences were seen 
for global quality of life, physical, emotional and role 
functioning, sleeping, and fatigue, again all favouring the 
rofecoxib groups (fi gure 4). Some of the changes in 
quality of life reported above were not more signifi cant in 
the dataset that included patients randomised up to 
Sept 30, 2004 (webappendix fi gure 2).
Discussion
The current study was based on a factorial design with 
two questions, one regarding the effi  cacy of a prolonged 
constant infusion of gemcitabine compared with standard 
30-min infusion and the other regarding the eff ect of 
adding rofecoxib to chemotherapy with cisplatin and 
gemcitabine. For both questions, results were negative 
because a survival diff erence was not noted in either. The 
study was not planned to test effi  cacy interactions in the 
experimental factors. Overall, because this—to our 
knowledge—was the fi rst randomised trial with the 
combination of COX-2 inhibitors and chemotherapy in 
advanced NSCLC, the trial design was done with an 
overoptimistic hypothesis (ie, a 0·67 HR of death in the 
experimental groups) and statistical power might be not 
suffi  cient to detect smaller eff ects.
PCI gemcitabine had previously been proposed as a way 
to improve the effi  cacy of this drug in a phase II trial in 
patients with pancreatic cancer, which showed interesting 
response and survival.10 To the best of our knowledge, our 
study is the fi rst phase III trial to test this hypothesis. Some 
other trials, also in patients with NSCLC, have been done 
without a control group or in the framework of a 
randomised phase II design, not allowing a formal 










Global quality of life Physical functioning Role functioning Emotional functioning Fatigue
Sleeping Pain Pain (elsewhere) Analgesic consumption Pain
(Visual analogue score)
c1–d8
0·04 0·07 0·03 0·42 0·04 0·02 0·24 0·22 0·02 0·42 0·24 0·15 0·02 0·52 0·91 0·74 0·006 0·04 0·15 0·29
0·004 0·27 0·40 0·53 0·0001 0·01 0·03 0·28 0·002 0·10 0·001 0·41 0·002 0·01 0·06 0·07 0·006 0·01 0·07 0·27 0·013
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Figure 4: Quality-of-life and pain analyses for rofecoxib versus non-rofecoxib groups
Only items for which statistical test was signifi cant in at least one timepoint are reported. Black numbers denote p values from the Wilcoxon rank sum tests. 
Improvement is indicated by positive changes. Please note that timing of pain assessment with the visual analogue score (box in right lower corner) is diff erent from 
the EORTC questionnaires (all the other boxes). In the x-axis labels, c denotes cycle, and d indicates day.
Articles
510 http://oncology.thelancet.com   Vol 8   June 2007
our analyses are suffi  cient to deny the hypothesis that 
prolonging the infusion time of gemcitabine can produce 
clinically relevant changes in effi  cacy in NSCLC.  
A notable amount of preclinical and non-experimental 
research have been published on the possibility that COX-
2-inhibiting drugs could be eff ective in the treatment of 
cancer. A clinical response of 65% has been reported in a 
neoadjuvant phase II study,32 which used the addition of 
another selective COX-2 inhibitor, celecoxib, to 
preoperative paclitaxel and carboplatin in 29 patients with 
stage IB to IIIA NSCLC. In another study, positive results 
in terms of response (24%, 95% CI 14–37) and 1-year 
survival (42%) were also reported with the combination of 
celecoxib and weekly paclitaxel as second-line treatment 
for NSCLC.33 In both of these studies, toxicity was 
apparently not worsened by the addition of celecoxib. 
Similar data were reported with celecoxib in combination 
with docetaxel.34,35 By contrast, celecoxib did not seem to 
enhance effi  cacy or improve patient-reported symptoms 
in a randomised phase II trial36 when com bined with 
docetaxel and irinotecan or gemcitabine and irinotecan in 
the second-line treatment of NSCLC. How ever, that study 
was not suffi  ciently powered to detect statistical 
diff erences between the regimens tested.  
The interest in testing the effi  cacy of COX-2 inhibitors in 
advanced cancer was clearly diminished when 
cardiovascular toxicity was reported in various large trials 
of chemoprevention.37–39 In particular, the Adeno -
matous Polyp Prevention on Vioxx (APPROVe) Trial 
(NCT00282386),39 which was designed to assess the 
hypothesis that 3 years of treatment with rofecoxib would 
decrease the risk of recurrent adenomatous polyps in 
patients with a history of colorectal adenomas, showed that 
the use of rofecoxib was associated with an increased risk 
of confi rmed thrombotic events—mainly myocardial 
infarctions and ischaemic cerebrovascular events. The 
increased relative risk became apparent after 18 months of 
treatment.39 Rofecoxib was consequently withdrawn by the 
manufacturer and leading drug agencies around the world. 
Obviously, this fi nding aff ected the GECO study, and the 
enrolment of patients in the rofecoxib groups was halted. 
Consequently, the fi nal sample for the analysis of the eff ect 
of rofecoxib was lower than planned; however, thanks to a 
longer follow-up, the actual numbers of events were close 
to the planned numbers needed for the fi nal analysis and 
statistical power was only slightly decreased to 79%. 
Unfortunately, prolongation of survival, the primary 
endpoint, was not reached. However, analyses of secondary 
endpoints, ie, quality of life, toxicity and response, deserve 
some comment. Quality-of-life analysis showed a general 
pattern favouring the addition of rofecoxib, although we 
should emphasise that some positive changes are 
dimensionally small and possibly under the thresholds 
that have been proposed for a diff erence to be clinically 
meaningful.40 Clearly, such positive eff ects are led by a 
better control of pain that, reasonably, positively aff ected 
global quality of life, physical and role functioning, and 
fatigue. We have previously shown that pain strongly 
correlates with global quality of life and functioning 
scales.41 Whether the positive eff ect on pain is simply due 
to the anti-infl ammatory and analgesic eff ects of rofecoxib 
or can pertain ultimately to some antineoplastic activity 
cannot be derived from this analysis. Treatment of pain is 
often inadequate at the beginning of treatment of lung 
cancer with chemotherapy, and the use of rofecoxib might 
have counteracted undertreatment.41 A weakness of quality-
of-life analysis that should be acknowledged is a trial design 
that did not include a placebo-controlled group. However, 
this decision was consistent with the fact that survival was 
chosen as primary endpoint and a placebo was not strictly 
needed to assess this endpoint. Additionally, the non-profi t 
nature of our trial made the inclusion of placebo groups a 
complex issue. 
Because of cardiovascular events reported in the 
APPROVe trial,39 toxicity analysis was especially challen-
ging. The APPROVe trial was run in a completely diff er-
ent context to our trial—ie, a chronic versus a fatal 
condition. Given the shorter survival of patients with 
advanced NSCLC, we could presume that our current study 
would have a very low chance of similar toxicities. But the 
patients with advanced NSCLC have several concomitant 
risk factors for cardiovascular morbidity, such as age and 
cigarette smoking; further more, the dose used in our 
study, which was based on previous reports,27,28 was 
double compared with that used in the APPROVe trial.39 
To provide the most toxicity infor mation available, we 
decided retrospectively not to limit analyses to summary 
measures (eg, heart general, according to Com-
mon Toxicity Criteria) that are commonly applied in 
cancer trials to report toxicity. Clearly the fi nal analyses 
can be biased because of the multiple testing of events 
that are ultimately related, and because of small numbers, 
which can only be counteracted partially by the application 
of exact statistical tests. Our data confi rm that a slight 
increase in the risk of ischaemic damage to the heart can 
be caused by the addition of rofecoxib. Although this did 
not translate into a signifi cant increment of toxic deaths 
(which were paradoxically more frequent in the control 
groups), future studies on COX-2 inhibitors in this popul-
ation of patients should be done with analogues that are 
less cardiotoxic than rofecoxib. Furthermore, new inform-
ation, such as better activity of COX-2 inhibitors in heavy 
smokers—taking into account that cigarette smoking 
induces COX-2 overexpression—should be considered.42
Our analysis of response suggests that further studies 
should be done. The current paradigm in clinical research 
on solid tumours is that whenever a signifi cant decrease of 
tumour mass occurs it can be attributed to the treatment 
eff ect. Therefore, even acknowledging that response is a 
soft endpoint and its value in advanced NSCLC is limited, 
our results are the strongest available evidence of an 
antineoplastic activity of a COX-2-inhibiting drug, to the 
best of our knowledge. Our fi nding, however, has some 
weaknesses. First, the study was not placebo-controlled 
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and investigators were aware of the assigned treatment; 
second, objective responses were not monitored 
independently and the response evaluation is based on 
measures given tumour-by-tumour by the investigators 
themselves; third, we did not succeed in collecting a 
suffi  cient number of tumour samples to do correlative 
studies and could not test whether the expression of COX-2 
was correlated with chance of response. Accepting that the 
noted diff erence is true, we can attempt some interpretation. 
The analysis of the target tumour response does strongly 
support the hypothesis that the eff ect of rofecoxib on 
tumour size is not limited to a small subgroup of patients 
(as could be expected for a target-based drug acting through 
a target that is present in a minority of patients), rather, 
this eff ect is shared by all the patients. Such behaviour 
might be the consequence of a drug that acts in a non-
specifi c way, for example, strengthening the cytotoxic 
activity of the other associated drugs, or through a target 
that is almost ubiquitous. Unsurprisingly, the diff erence in 
response does not translate into a survival advantage in 
this study. Johnson and colleagues43 have recently shown, 
in an elegant review of 191 trials of lung cancer treatment, 
that the threshold value in the absolute diff erence of 
response that is needed to actually translate into a survival 
diff erence is about 30% in a trial the size of the current 
one. 
Our study shows that the prolonged and constant 
infusion of gemcitabine is not more eff ective than standard 
infusion in 30 min, and we believe that further studies on 
this point are not recommended. Similarly, the addition of 
rofecoxib to chemotherapy did not improve survival. 
However, for the latter issue, provocative results of 
secondary analyses suggest that further trials on the value 
of COX-2-inhibiting drugs in the treatment of solid 
tumours should be considered, possibly with drugs that 
are less cardiotoxic than rofecoxib. By reviewing estab-
lished trial registries (http://clinicaltrials.gov, acc essed 
May 2, 2007) many clinical trials seem to be ongoing that 
investigate the role of celecoxib in diff erent tumours 
(NSCLC, prostate, breast, colorectal, head and neck cancer, 
sarcomas, brain tumours), as neoadjuvant, adju vant or 
metastatic treatment, in combination with chemo therapy, 
hormone treatment, radiotherapy, or target-based agents. 
The results of these studies should better defi ne the role 
of COX-2 inhibitors in the treatment of solid tumours. 
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